Regeneron Pharmaceuticals (REGN) Other Non Operating Income (2013 - 2026)

Regeneron Pharmaceuticals' Other Non Operating Income history runs 14 years deep, the most recent figure standing at $201.2 million for Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 37.52% year-over-year to $201.2 million in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 31.21% increase from a year earlier, with the FY2025 full-year figure at $1.7 billion, up 100.92% from the prior year.
• Other Non Operating Income climbed to $201.2 million in Q1 2026 per REGN's latest filing, from $176.0 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $755.8 million in Q3 2025 and bottomed at -$183.8 million in Q1 2022.
• The 5-year median for Other Non Operating Income is $184.5 million (2023), against an average of $198.8 million.
• Across the five-year window, Other Non Operating Income tumbled 92000.0% in 2022 and soared 1759.66% in 2024, its largest moves.
• Year by year, Other Non Operating Income stood at -$183.8 million in 2022, then jumped by 205.01% to $193.0 million in 2023, then sank by 111.19% to -$21.6 million in 2024, then soared by 914.81% to $176.0 million in 2025, then climbed by 14.32% to $201.2 million in 2026.
• Per Business Quant, the three latest REGN Other Non Operating Income figures stand at $201.2 million (Q1 2026), $176.0 million (Q4 2025), and $755.8 million (Q3 2025).